Advanced Search

Project: Screening for HIV Infection in Pregnant Women [Entered Retrospectively]

Public Report Complete

Project Summary

Title and Description

Key Questions

Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Key Questions 1-5 Sara Grusing 1, 2, 3, 4, 5

Associated Studies (each link opens a new tab)

Title Author Year
Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy. Aaron E., Bonacquisti A., Mathew L., Alleyne G., Bamford LP., Culhane JF. 2012
Antiretroviral combination use during pregnancy and the risk of major congenital malformations. BĂ©rard A., Sheehy O., Zhao JP., Abrahamowicz M., Loutfy M., Boucoiran I., Bernatsky S. 2017
PMTCT Option B+ Does Not Increase Preterm Birth Risk and May Prevent Extreme Prematurity: A Retrospective Cohort Study in Malawi. Chagomerana MB., Miller WC., Pence BW., Hosseinipour MC., Hoffman IF., Flick RJ., Tweya H., Mumba S., Chimbwandira F., Powers KA. 2017
Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. Chen JY., Ribaudo HJ., Souda S., Parekh N., Ogwu A., Lockman S., Powis K., Dryden-Peterson S., Creek T., Jimbo W., Madidimalo T., Makhema J., Essex M., Shapiro RL. 2012
The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations. Duryea E., Nicholson F., Cooper S., Roberts S., Rogers V., McIntire D., Sheffield J., Stewart R. 2015
Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. Floridia M., Mastroiacovo P., Tamburrini E., Tibaldi C., Todros T., Crepaldi A., Sansone M., Fiscon M., Liuzzi G., Guerra B., Vimercati A., Vichi F., Vicini I., Pinnetti C., Marconi AM., Ravizza M. 2013
Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting? Kakkar F., Boucoiran I., Lamarre V., Ducruet T., Amre D., Soudeyns H., Lapointe N., Boucher M. 2015
Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Knapp KM., Brogly SB., Muenz DG., Spiegel HM., Conway DH., Scott GB., Talbot JT., Shapiro DE., Read JS. 2012
Predictors of adverse pregnancy outcomes in women infected with HIV in Latin America and the Caribbean: a cohort study. Kreitchmann R., Li SX., Melo VH., Fernandes Coelho D., Watts DH., Joao E., Coutinho CM., Alarcon JO., Siberry GK. 2014
Antiretroviral Therapy in Relation to Birth Outcomes among HIV-infected Women: A Cohort Study. Li N., Sando MM., Spiegelman D., Hertzmark E., Liu E., Sando D., Machumi L., Chalamilla G., Fawzi W. 2016
Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. Lopez M., Figueras F., Hernandez S., Lonca M., Garcia R., Palacio M., Coll O. 2012
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. Moodley T., Moodley D., Sebitloane M., Maharaj N., Sartorius B. 2016
Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy Is Not Associated With Adverse Perinatal Outcomes Among HIV-infected East African Women: A Prospective Study. Pintye J., Baeten JM., Celum C., Mugo N., Ngure K., Were E., Bukusi EA., John-Stewart G., Heffron RA. 2017
In Utero ART Exposure and Birth and Early Growth Outcomes Among HIV-Exposed Uninfected Infants Attending Immunization Services: Results From National PMTCT Surveillance, South Africa. Ramokolo V., Goga AE., Lombard C., Doherty T., Jackson DJ., Engebretsen IM. 2017
Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. Short CE., Douglas M., Smith JH., Taylor GP. 2014
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. Siberry GK., Williams PL., Mendez H., Seage GR., Jacobson DL., Hazra R., Rich KC., Griner R., Tassiopoulos K., Kacanek D., Mofenson LM., Miller T., DiMeglio LA., Watts DH. 2012
Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy. Zash R., Jacobson DL., Diseko M., Mayondi G., Mmalane M., Essex M., Petlo C., Lockman S., Makhema J., Shapiro RL. 2017
Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana. Zash R., Souda S., Chen JY., Binda K., Dryden-Peterson S., Lockman S., Mmalane M., Makhema J., Essex M., Shapiro R. 2016
In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial. Sibiude J., Le Chenadec J., Bonnet D., Tubiana R., Faye A., Dollfus C., Mandelbrot L., Delmas S., Lelong N., Khoshnood B., Warszawski J., Blanche S. 2015
Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). Sibiude J., Mandelbrot L., Blanche S., Le Chenadec J., Boullag-Bonnet N., Faye A., Dollfus C., Tubiana R., Bonnet D., Lelong N., Khoshnood B., Warszawski J. 2014
Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Sibiude J., Warszawski J., Tubiana R., Dollfus C., Faye A., Rouzioux C., Teglas JP., Ekoukou D., Blanche S., Mandelbrot L. 2012
Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. Lipshultz SE., Williams PL., Zeldow B., Wilkinson JD., Rich KC., van Dyke RB., Seage GR., Dooley LB., Kaltman JR., Siberry GK., Mofenson LM., Shearer WT., Colan SD. 2015
Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age. Nozyce ML., Huo Y., Williams PL., Kapetanovic S., Hazra R., Nichols S., Hunter S., Smith R., Seage GR., Sirois PA. 2014
Combination antiretroviral use and preterm birth. Watts DH., Williams PL., Kacanek D., Griner R., Rich K., Hazra R., Mofenson LM., Mendez HA. 2013
Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. Williams PL., Crain MJ., Yildirim C., Hazra R., Van Dyke RB., Rich K., Read JS., Stuard E., Rathore M., Mendez HA., Watts DH. 2015
Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design. Williams PL., Hazra R., Van Dyke RB., Yildirim C., Crain MJ., Seage GR., Civitello L., Ellis A., Butler L., Rich K. 2016
Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries. Sartorius BK., Chersich MF., Mwaura M., Meda N., Temmerman M., Newell ML., Farley TM., Luchters S. 2013
Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. Chiappini E., Galli L., Giaquinto C., Ene L., Goetghebuer T., Judd A., Lisi C., Malyuta R., Noguera-Julian A., Ramos JT., Rojo-Conejo P., Rudin C., Tookey P., de Martino M., Thorne C. 2013
Factors responsible for mother-to-child HIV transmission in Ontario, Canada, 1996-2008. Lu D., Liu J., Samson L., Bitnun A., Seigel S., Brophy J., Leonard L., Remis RS. 2014
Mother-to-child HIV transmissions in Israel, 1985-2011. Mor Z., Sheffer R., Chemtob D. 2017
Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland. Tookey PA., Thorne C., van Wyk J., Norton M. 2016
No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Mandelbrot L., Tubiana R., Le Chenadec J., Dollfus C., Faye A., Pannier E., Matheron S., Khuong MA., Garrait V., Reliquet V., Devidas A., Berrebi A., Allisy C., Elleau C., Arvieux C., Rouzioux C., Warszawski J., Blanche S. 2015
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. Fowler MG., Qin M., Fiscus SA., Currier JS., Flynn PM., Chipato T., McIntyre J., Gnanashanmugam D., Siberry GK., Coletti AS., Taha TE., Klingman KL., Martinson FE., Owor M., Violari A., Moodley D., Theron GB., Bhosale R., Bobat R., Chi BH., Strehlau R., Mlay P., Loftis AJ., Browning R., Fenton T., Purdue L., Basar M., Shapiro DE., Mofenson LM. 2016
Antiretroviral Pregnancy Registry Interim Report for 1 January 1989 through 31 January 2018 Antiretroviral Pregnancy Registry Steering Committee 2018
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine. Rough K., Seage GR., Williams PL., Hernandez-Diaz S., Huo Y., Chadwick EG., Currier JS., Hoffman RM., Barr E., Shapiro DE., Patel K. 2018
Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age. Snijdewind IJM., Smit C., Godfried MH., Bakker R., Nellen JFJB., Jaddoe VWV., van Leeuwen E., Reiss P., Steegers EAP., van der Ende ME. 2018

Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: